Medical Marijuana for Autoimmune Diseases in Florida
Conditions where the immune system mistakenly attacks healthy body tissues.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Autoimmune diseases encompass over 80 conditions in which the immune system mistakenly targets and attacks the body's own healthy cells and tissues. Common autoimmune conditions include rheumatoid arthritis, lupus (systemic lupus erythematosus), psoriasis, Hashimoto's thyroiditis, Type 1 diabetes, celiac disease, Sjogren's syndrome, and scleroderma. These conditions can affect virtually any organ system and typically cause chronic inflammation, pain, fatigue, and progressive tissue damage.
Autoimmune diseases collectively affect more than 24 million Americans and are often managed with immunosuppressive medications — including corticosteroids, methotrexate, and biologics like Humira and Enbrel — that reduce immune system activity but also increase vulnerability to infections and carry significant side effect profiles. Many patients cycle through multiple medications seeking adequate disease control, and some experience only partial symptom relief despite aggressive treatment that costs tens of thousands of dollars annually.
Autoimmune conditions qualify for medical marijuana in Florida under various provisions — arthritis and MS are explicitly named, while conditions like lupus, psoriasis, and others qualify under the "comparable conditions" provision of Statute 381.986. The endocannabinoid system serves as a critical regulator of immune function, making cannabinoid therapy mechanistically relevant to autoimmune pathology.
How Medical Cannabis May Help
The endocannabinoid system serves as a critical regulator of immune function, making cannabinoid therapy directly relevant to autoimmune pathology. Both THC and CBD have demonstrated immunomodulatory properties — helping to calm overactive immune responses without completely suppressing immune function as some conventional drugs do. Research published in Cell Death & Disease (Lowin et al., 2020) showed that CBD increases intracellular calcium and reduces cell viability in rheumatoid arthritis synovial fibroblasts while reducing production of inflammatory IL-6, IL-8, and MMP-3. Critically, the effect was enhanced under inflammatory conditions, meaning CBD preferentially targets activated, pro-inflammatory cells while sparing healthy tissue. CB2 receptors are densely expressed on immune cells including T cells, B cells, macrophages, and dendritic cells. Cannabinoid activation of CB2 suppresses release of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) while upregulating anti-inflammatory IL-10. Cannabinoids can also suppress T-cell proliferation and shift immune responses away from Th1/Th17 (pro-inflammatory) toward Th2/Treg (regulatory) profiles — directly relevant to autoimmune pathology. Both THC and CBD also inhibit the NF-kB signaling pathway, a master regulator of inflammatory gene expression. Medical cannabis can reduce chronic inflammation, alleviate autoimmune-related pain, improve fatigue and energy levels, and address the anxiety, depression, and sleep disturbances commonly associated with living with a chronic autoimmune condition. CBD-dominant formulations may be particularly appropriate for their anti-inflammatory effects with minimal psychoactive impact. Dr. Stratt works with each patient's rheumatologist, immunologist, or specialist to ensure cannabis therapy complements their existing treatment plan.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and specialist records (rheumatologist, immunologist, endocrinologist) documenting your specific autoimmune condition, laboratory results, and current medication list.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for Autoimmune Diseases
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.